基于网络药理学和分子对接法探讨黄芪治疗前列腺癌的机制
Exploring the Mechanism of Astragalus membranaceus in the Treatment of Prostate Cancer Based on Network Pharmacology and Molecular Docking
DOI: 10.12677/ACM.2022.1291255, PDF,   
作者: 程晓金, 王春洋, 牛潇菲, 陆 莹:天津中医药大学第一附属医院,国家中医针灸临床医学研究中心,天津;李小江*:天津中医药大学第一附属医院,天津
关键词: 黄芪前列腺癌网络药理学分子对接Astragalus membranaceus Prostate Cancer Network Pharmacology Molecular Docking
摘要: 运用网络药理学与分子对接探索黄芪治疗前列腺癌的作用机制。方法:通过借助中药系统药理学数据库及分析平台(TCMSP)筛选黄芪的成分及作用靶点,使用OMIM和GeneCards数据库筛选HT靶点;采用Cytoscape软件构建化学成分–潜在靶点网络图和蛋白相互作用网络图,进而筛选出关键靶点,借助DAVID数据库对靶点进行GO分析和KEGG通路分析;使用AutoDock Vina进行分子对接,初步筛选并进一步验证黄芪中的核心化学成分。结果:从黄芪中得到16个活性化合物及;筛选出与前列腺癌相关作用靶点172个;黄芪可以通过调节AGE-RAGE信号通路、PI3K-Akt信号通路、IL-17信号通路、MAPK信号通路、肿瘤坏死因子信号通路等对前列腺癌发挥治疗作用。其中CCND1、MYC、MAPK1、AKT1、ESR1、TNF、RELA、TP53、RB1、IL6、JUN、FOS、MAPK14等基因可能为关键靶点;分子对接结果显示:槲皮素与FOS蛋白的亲和力较好。结论:黄芪治疗前列腺癌的潜在作用机制具有多成分–多靶点–多通路的特点,为阐述黄芪治疗前列腺癌的作用机制和开展进一步研究提供依据。
Abstract: Objective: Using network pharmacology and molecular docking to explore the mechanism of Astragalus membranaceus in the treatment of prostate cancer. Methods: The components and action targets of Astragalus membranaceus were screened by the pharmacological database and analysis platform (TCMSP), and the HT targets were screened by OMIM and GeneCards database. Cytoscape software was used to construct the chemical components-potential target network and protein in-teraction network, and then the key targets were screened out. The GO analysis and KEGG pathway analysis of the targets were performed with the help of DAVID database. AutoDock Vina was used for molecular docking to preliminarily screen and further to verify the core chemical components in Astragalus membranaceus. Results: Sixteen active compounds were obtained from Astragalus membranaceus. 172 targets related to prostate cancer were screened out. Astragalus membranus can play a therapeutic role in prostate cancer by regulating AGE-RAGE signaling pathway, PI3K-Akt signaling pathway, IL-17 signaling pathway, MAPK signaling pathway, tumor necrosis factor signal-ing pathway, etc. Among them, CCND1, MYC, MAPK1, Akt1, ESR1, TNF, RELA, TP53, RB1, IL6, Jun, FOS, MAPK14 and other genes may be key targets. The results of molecular docking showed that quercetin had a good affinity with FOS protein. Conclusion: The potential mechanism of Astragalus membranaceus in the treatment of prostate cancer has the characteristics of multi-component, mul-ti-target and multi-pathway, which provides the basis for further study on the mechanism of Astragalus membranaceus in the treatment of prostate cancer.
文章引用:程晓金, 王春洋, 牛潇菲, 陆莹, 李小江. 基于网络药理学和分子对接法探讨黄芪治疗前列腺癌的机制[J]. 临床医学进展, 2022, 12(9): 8695-8706. https://doi.org/10.12677/ACM.2022.1291255

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] Zhang, S., Zhao, S. and Fu, X. (2019) Intensity Modulated Radiotherapy in Combination with Endocrinotherapy in the Treatment of Middle and Advanced Prostatic Cancer. Pakistan Journal of Medical Sciences, 35, 1264-1269. [Google Scholar] [CrossRef] [PubMed]
[3] Bonkhoff, H. (2018) Estrogen Receptor Signaling in Prostate Cancer: Implications for Carcinogenesis and Tumor Progression. Prostate, 78, 2-10. [Google Scholar] [CrossRef] [PubMed]
[4] Dai, C., Heemers, H. and Sharifi, N. (2017) Androgen Signaling in Pros-tate Cancer. Cold Spring Harbor Perspectives in Medicine, 7, a030452. [Google Scholar] [CrossRef] [PubMed]
[5] 李宁, 肖国有. 前列腺癌骨转移治疗的研究进展[J]. 肿瘤防治研究, 2020, 47(8): 641-646.
[6] 宋竖旗, 李灿, 刘昭文, 等. 中西医结合治疗去势抵抗性前列腺癌[J]. 中医学报, 2020, 35(11): 2285-2289.
[7] 刘德果, 陈其华, 李博. 益肾通癃汤联合中医外治对中老年前列腺癌骨转移临床疗效研究[J]. 辽宁中医药大学学报, 2021, 23(4): 83-87.
[8] 顾坚毅, 谈鸣岳, 葛旻垚, 等. 加味参芪地黄汤对去势后激素敏感性前列腺癌骨转移患者的疗效研究[J]. 中华男科学杂志, 2021, 27(2): 161-166.
[9] 陈浩然, 刘浩. 中医药防治去势抵抗性前列腺癌的思路与方法[J]. 中华中医药学刊, 2021, 39(3): 164-168.
[10] 车琳琳, 李想, 董婉茹, 等. 中医药对前列腺癌信号通路的调控作用[J]. 上海中医药杂志, 2019, 53(11): 98-104.
[11] 陈炽炜, 林曼迪, 刘昊, 等. 去势抵抗性前列腺癌患者的中医证型分布及其早期进展原因的多因素分析[J]. 广州中医药大学学报, 2020, 37(7): 1241-1247.
[12] 王泽帆. 前列腺癌患者的中医体质类型分析[D]: [硕士学位论文]. 广州: 广州中医药大学, 2019.
[13] 张瑶, 李小江, 贾英杰. 中医“健脾利湿化瘀法”在前列腺癌治疗中的运用[J]. 天津中医药, 2021, 38(3): 317-321.
[14] 毛倩倩, 林久茂. 黄芪多糖抗肿瘤作用的研究进展[J]. 中医药通报, 2020, 19(4): 69-72.
[15] 秦书敏, 林静瑜, 黄可儿. 黄芪的免疫调节作用研究概述[J]. 中华中医药学刊, 2017, 35(3): 699-702.
[16] 李小江, 冯梦晗, 牟睿宇, 等. “健脾利湿化瘀法”治疗中晚期前列腺癌内分泌治疗后部分雄激素缺乏综合征的临床观察[J]. 中草药, 2020, 51(21): 5559-5565.
[17] 张瑶, 许月梅, 李家合, 等. 基于PI3K/AKT/eNOS信号通路探讨健脾利湿化瘀方抑制前列腺癌血管生成的实验研究[J]. 天津中医药, 2021, 38(4): 522-527.
[18] 吴坚, 薛晓燕, 王丽芳, 等. 分子对接方法应用与发展[J]. 亚太传统医药, 2013, 9(12): 80-81.
[19] 马璐, 田国祥, 耿辉, 等. 中药系统药理数据库TCMSP及其分析应用简介[J]. 中国循证心血管医学杂志, 2020, 12(12): 1413-1416.
[20] Ma, C., Wang, L. and Xie, X. (2011) GPU Accelerated Chemical Similarity Calculation for Compound Library Comparison. Journal of Chemical Information and Modeling, 51, 1521-1527. [Google Scholar] [CrossRef] [PubMed]
[21] Xu, X., Zhang, W., Huang, C., et al. (2012) A Novel Chemometric Method for the Prediction of Human Oral Bioavailability. International Journal of Molecular Sciences, 13, 6964-6982. [Google Scholar] [CrossRef] [PubMed]
[22] Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[23] 司富春, 杜超飞. 前列腺癌的中医证候和方药规律分析[J]. 中华中医药杂志, 2015, 30(2): 581-585.
[24] 陈刚. 中医扶正抑瘤法治疗晚期前列腺癌疗效分析[J]. 中医临床研究, 2017, 9(12): 131-132.
[25] 朱秀, 邓松华. 前列腺癌发病与基因关联的研究进展[J]. 医学综述, 2011, 17(11): 1648-1651.
[26] 白璐, 张森, 卢亚乐, 等. 前列腺癌发病机制中信号通路的研究进展[J]. 中国医学工程, 2020, 28(9): 39-43.
[27] 于玲, 王知斌, 王秋红, 等. 黄芪中黄酮类化合物药理作用研究进展[J]. 中医药信息, 2018, 35(2): 104-108.
[28] 郑雪花, 姜赞, 王小雨, 等. 黄酮类化合物对AKR1C3抑制作用的研究[J]. 今日药学, 2018, 28(8): 505-509.
[29] 邢红宇, 朱明月, 李伟, 等. 槲皮素调控GSTP1甲基化抑制前列腺癌LNCap细胞增殖的机制研究[J]. 安徽医科大学学报, 2020, 55(12): 1921-1925.
[30] 宋静, 白吉祥, 王书惠, 等. 槲皮素对人前列腺癌PC-3细胞自噬及磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路的影响[J]. 中国医学科学院学报, 2020, 42(5): 578-584.
[31] 王康静. 槲皮素对人前列腺癌PC-3裸鼠移植瘤的实验性疗效[D]: [硕士学位论文]. 南京: 南京中医药大学, 2014.
[32] 仇炜, 雷宇华, 张宁, 等. 山柰酚抑制人前列腺癌PC-3细胞迁移及其作用机制[J]. 中国老年学杂志, 2011, 31(20): 3972-3975.
[33] 谭蓓蓓, 郭婧澜, 刘倩, 等. 山柰酚对前列腺癌骨转移模型小鼠的作用及其机制研究[J]. 中国临床药理学杂志, 2020, 36(3): 293-296.
[34] Liu, X.J., Li, Y.Q., Chen, Q.Y., et al. (2014) Up-Regulating of RASD1 and Apoptosis of DU-145 Human Prostate Cancer Cells Induced by For-mononetin in Vitro. Asian Pacific Journal of Cancer Prevention, 15, 2835-2839. [Google Scholar] [CrossRef
[35] Li, T., Zhao, X., Mo, Z., et al. (2014) Formononetin Promotes Cell Cycle Arrest via Downregulation of Akt/Cyclin D1/CDK4 in Human Prostate Cancer Cells. Cellular Physiology and Biochemistry, 34, 1351-1358. [Google Scholar] [CrossRef] [PubMed]
[36] 邱忠凯, 谭淼, 梁伟, 等. 前列腺癌组织中miR-34b、Cyclin D1 mRNA表达变化及其意义[J]. 山东医药, 2019, 59(15): 78-80.
[37] 吴大森, 白金玲, 张俊, 等. N-Myc促进前列腺癌神经内分泌转化的研究进展[J]. 中外医疗, 2020, 39(26): 196-198.
[38] 胡波. MicroRNA-212通过MAPK1途径抑制前列腺癌细胞增殖和侵袭的机制研究[D]: [博士学位论文]. 济南: 山东大学, 2018.
[39] 张丽娟. AKT1/2在去势抵抗性前列腺癌进展中的作用研究[D]: [博士学位论文]. 新乡: 新乡医学院, 2019.
[40] 赵谊宁. 雌激素受体ESR1在前列腺癌组织中表达及分布的研究[D]: [硕士学位论文]. 南京: 东南大学, 2016.
[41] 袁佳璐. RB1基因表达对前列腺癌LNCaP细胞系生物学行为及药物敏感性的影响[D]: [硕士学位论文]. 大连: 大连医科大学, 2020.
[42] 李金贵, 马利, 熊兵红, 等. IL-6调节miR-21在激素抵抗性前列腺癌中的机制研究[J]. 西部医学, 2013, 25(10): 1458-1463.
[43] Seki, E., Brenner, D.A. and Karin, M. (2012) A Liver Full of JNK: Signaling in Regulation of Cell Function and Disease Pathogenesis, and Clinical Approaches. Gastroenterology, 143, 307-320. [Google Scholar] [CrossRef] [PubMed]
[44] Rodrigues, G.A., Park, M. and Schlessinger, J. (1997) Activation of the JNK Pathway Is Essential for Transformation by the Met Oncogene. EMBO Journal, 16, 2634-2645. [Google Scholar] [CrossRef] [PubMed]
[45] Behrens, A., Jochum, W., Sibilia, M., et al. (2000) Oncogenic Transformation by Ras and Fos Is Mediated by c-Jun N-Terminal Phosphorylation. Oncogene, 19, 2657-2663. [Google Scholar] [CrossRef] [PubMed]
[46] Bubici, C. and Papa, S. (2014) JNK Signalling in Cancer: In Need of New, Smarter Therapeutic Targets. British Journal of Pharmacology, 171, 24-37. [Google Scholar] [CrossRef] [PubMed]
[47] Wu, X., He, Y., Zhang, G., et al. (2018) Royleanone Diterpenoid Exhibits Potent Anticancer Effects in LNCaP Human Prostate Carcinoma Cells by Inducing Mitochondrial Mediated Apoptosis, Cell Cycle Arrest, Suppression of Cell Migration and Downregulation of mTOR/PI3K/AKT Signalling Pathway. Journal of B.U.O.N.: Official Journal of the Balkan Union of Oncology, 23, 1055-1060.
[48] Pfeil, K., Eder, I.E., Putz, T., et al. (2004) Long-Term Androgen-Ablation Causes Increased Resistance to PI3K/Akt Pathway Inhibition in Prostate Cancer Cells. Prostate, 58, 259-268. [Google Scholar] [CrossRef] [PubMed]
[49] 张瑶, 李家合. PI3K/AKT信号通路与前列腺癌关系的研究进展[J]. 肿瘤学杂志, 2021, 27(2): 153-157.
[50] 包继明. AGE-RAGE激活PI3K/Akt通路调控视网膜母细胞瘤蛋白促进前列腺癌细胞增殖的机制研究[D]: [硕士学位论文]. 广州: 南方医科大学, 2014.
[51] 高杰, 丁留成, 卫中庆. 脂质代谢在去势抵抗性前列腺癌中的研究进展[J]. 东南国防医药, 2021, 23(2): 169-174.
[52] Kuemmerle, N.B., Rysman, E., Lombardo, P.S., et al. (2011) Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation. Molecular Cancer Therapeutics, 10, 427-436. [Google Scholar] [CrossRef
[53] Gazi, E., Gardner, P.L., Ockyer, N.P., et al. (2007) Direct Evidence of Lipid Translocation between Adipocytes and Prostate Cancer Cells with Imaging FTIR Microspectroscopy. Journal of Lipid Research, 48, 1846-1856. [Google Scholar] [CrossRef
[54] Ostergren, P.B., Kistorp, C., Fode, M., et al. (2019) Metabolic Consequences of Gonadotropin-Releasing Hormone Agonists vs Orchiectomy: A Randomized Clinical Study. BJU In-ternational, 123, 602-611. [Google Scholar] [CrossRef] [PubMed]
[55] 刘杰, 刘艳波, 杨丽娟, 等. 细胞因子IL-17E、IL-17F及其受体在前列腺癌组织中的表达及意义[J]. 北华大学学报(自然科学版), 2020, 21(3): 338-342.
[56] 徐锐, 王莉, 李满祥. 白细胞介素-17在前列腺癌组织中的表达及临床意义[J]. 宁夏医科大学学报, 2017, 39(7): 756-759.
[57] 陈海蛟, 王浩, 张立, 等. MAPK信号通路在表皮生长因子调控人前列腺癌PC-3细胞黏附、迁移、侵袭的作用[J]. 复旦学报(医学版), 2006(2): 175-178.